Is There a Risk of Lymphoma Associated With Anti-tumor Necrosis Factor Drugs in Patients With Inflammatory Bowel Disease? A Systematic Review of Observational Studies
Background: Inflammatory bowel diseases (IBDs) are generally not considered a risk factor for the development of lymphoma. When considering IBD treatments, there is good evidence supporting thiopurines (azathioprine, 6-mercaptopurine) as a risk factor for lymphoma. Conversely, the association betwee...
Saved in:
Main Authors: | Sara Ferraro (Author), Luca Leonardi (Author), Irma Convertino (Author), Corrado Blandizzi (Author), Marco Tuccori (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2019-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline
by: Marco Tuccori, et al.
Published: (2020) -
Assessing disease activity of rheumatoid arthritis patients and drug-utilization patterns of biologic disease-modifying antirheumatic drugs in the Tuscany region, Italy
by: Irma Convertino, et al.
Published: (2023) -
Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis
by: Irma Convertino, et al.
Published: (2023) -
Signal management and risk minimization strategy: a case study on obinutuzumab and non-overt disseminated intravascular coagulation
by: Giulia Valdiserra, et al.
Published: (2023) -
Novel Pharmacological Therapy in Inflammatory Bowel Diseases: Beyond Anti-Tumor Necrosis Factor
by: Cristiano Pagnini, et al.
Published: (2019)